RSS
MKM Upgrades Merck to a “Buy” (MRK)
MKM reported on Tuesday that they have upgraded healthcare company, Merck & Co., Inc.(MRK
) to a “Buy”.
The firm reported that they have upgraded MRK from “Neutral” to a “Buy,” and have given the company a price target of $51. This price target suggests a 15% increase over the stock’s current price of $43.38.
Merck & Co. shares were mostly flat during premarket trading Tuesday. The stock is up 14.96% YTD.
The Bottom Line
Shares of Merck (MRK) have a 3.81% dividend yield, based on last night’s closing stock price of $43.34. The stock has technical support in the $41-$42 price area. If the shares can firm up, we see overhead resistance around the $46-$48 price levels.
Merck & Co., Inc.(MRK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
FREE Dividend Stock Newsletter
Get the Dividend.com email newsletter to receive:
- A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
- Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
- Tons of great market analysis and recommendations
MOST POPULAR ARTICLES ON DIVIDEND.COM
ABOUT THIS ARTICLE
THE BEST DIVIDEND STOCKS
Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the 
ADVERTISING PARTNERS
